Skip to main content
All lobbying filings

LYKOS THERAPEUTICS

Lobbying for LYKOS THERAPEUTICS · Healthcare/pharmaceuticals

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $90,000.00 expenses · posted Apr 21, 2025

Official filing document

 Lobbying activity 4
Budget/Appropriations

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating innovative mental health challenges, including PTSD (no bill); Fiscal Year 2026 Military Construction, Veterans Affairs and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development) (no bill number).

Defense

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating innovative mental health challenges, including PTSD (no bill); Fiscal Year 2026 Military Construction, Veterans Affairs and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development) (no bill number).

Health Issues

Fiscal Year 2026 Commerce, Justice, Science and Related Agencies Appropriations Act (issues related to potential improvements to Food & Drug Administration and Drug Enforcement Administration processes for rescheduling of controlled substances) (no bill number).

Veterans

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating innovative mental health challenges, including PTSD (no bill); Fiscal Year 2026 Military Construction, Veterans Affairs and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development) (no bill number).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem